Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma
Abstract For locally advanced intrahepatic cholangiocarcinoma (ICC), the combination of cisplatin plus gemcitabine (CisGem) is the standard first-line treatment. However, the outcome remains unsatisfied with the median overall survival (OS) of 11.7 months. We aimed to compare the effect of CisGem re...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-09586-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402605852164096 |
|---|---|
| author | Lin Liu Huanhuan Wang Liang Sun Yufang Liu Yujing Zhang Xutian Wang Xin Zheng |
| author_facet | Lin Liu Huanhuan Wang Liang Sun Yufang Liu Yujing Zhang Xutian Wang Xin Zheng |
| author_sort | Lin Liu |
| collection | DOAJ |
| description | Abstract For locally advanced intrahepatic cholangiocarcinoma (ICC), the combination of cisplatin plus gemcitabine (CisGem) is the standard first-line treatment. However, the outcome remains unsatisfied with the median overall survival (OS) of 11.7 months. We aimed to compare the effect of CisGem regimen and hepatic arterial infusion chemotherapy (HAIC) with Folfox 4 for locally advanced ICC. 97 Locally advanced ICC patients treated by CisGem regimen or HAIC with Folfox 4 in our institution from 2017 to 2019 were studied as training group. 43 locally advanced ICCs receiving CisGem chemotherapy or HAIC with Folfox 4 were investigated as validation group. The median OS was 14.5 months among 37 ICC patients from the HAIC group and 10.3 months among 60 ICC cases in the CisGem group. The median PFS in the HAIC group was 8.2 months in contrast to 5.3 months in the CisGem group. Additionally, objective response rate (ORR) in the HAIC group was markedly better than one in the CisGem group (29.7% v 5.0%). Patients from the HAIC group suffered from less AE (particularly 3–4 grade AE) than those in the CisGem group. The prediction nomogram models for OS and PFS were built respectively after Cox multivariate analysis, which were confirmed to be clinically useful by external validation cohort. These data here suggested HAIC with Folfox 4 was a potential first-line treatment option for local advanced ICC. |
| format | Article |
| id | doaj-art-7bc25d1287964689bceaf010abb87d4d |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-7bc25d1287964689bceaf010abb87d4d2025-08-20T03:37:30ZengNature PortfolioScientific Reports2045-23222025-07-0115111310.1038/s41598-025-09586-8Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinomaLin Liu0Huanhuan Wang1Liang Sun2Yufang Liu3Yujing Zhang4Xutian Wang5Xin Zheng6Department of Anesthesiology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Hepatobiliary Surgery, Nanzheng People HospitalDepartment of Hepatobiliary Surgery, Shangluo Central HospitalDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityAbstract For locally advanced intrahepatic cholangiocarcinoma (ICC), the combination of cisplatin plus gemcitabine (CisGem) is the standard first-line treatment. However, the outcome remains unsatisfied with the median overall survival (OS) of 11.7 months. We aimed to compare the effect of CisGem regimen and hepatic arterial infusion chemotherapy (HAIC) with Folfox 4 for locally advanced ICC. 97 Locally advanced ICC patients treated by CisGem regimen or HAIC with Folfox 4 in our institution from 2017 to 2019 were studied as training group. 43 locally advanced ICCs receiving CisGem chemotherapy or HAIC with Folfox 4 were investigated as validation group. The median OS was 14.5 months among 37 ICC patients from the HAIC group and 10.3 months among 60 ICC cases in the CisGem group. The median PFS in the HAIC group was 8.2 months in contrast to 5.3 months in the CisGem group. Additionally, objective response rate (ORR) in the HAIC group was markedly better than one in the CisGem group (29.7% v 5.0%). Patients from the HAIC group suffered from less AE (particularly 3–4 grade AE) than those in the CisGem group. The prediction nomogram models for OS and PFS were built respectively after Cox multivariate analysis, which were confirmed to be clinically useful by external validation cohort. These data here suggested HAIC with Folfox 4 was a potential first-line treatment option for local advanced ICC.https://doi.org/10.1038/s41598-025-09586-8Hepatic arterial infusion chemotherapyIntrahepatic cholangiocarcinomaFolfox 4GemcitabineCisplatin |
| spellingShingle | Lin Liu Huanhuan Wang Liang Sun Yufang Liu Yujing Zhang Xutian Wang Xin Zheng Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma Scientific Reports Hepatic arterial infusion chemotherapy Intrahepatic cholangiocarcinoma Folfox 4 Gemcitabine Cisplatin |
| title | Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| title_full | Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| title_fullStr | Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| title_full_unstemmed | Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| title_short | Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| title_sort | hepatic arterial infusion chemotherapy with folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma |
| topic | Hepatic arterial infusion chemotherapy Intrahepatic cholangiocarcinoma Folfox 4 Gemcitabine Cisplatin |
| url | https://doi.org/10.1038/s41598-025-09586-8 |
| work_keys_str_mv | AT linliu hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT huanhuanwang hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT liangsun hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT yufangliu hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT yujingzhang hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT xutianwang hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma AT xinzheng hepaticarterialinfusionchemotherapywithfolfox4regimenversuscisplatinandgemcitabineforlocallyadvancedintrahepaticcholangiocarcinoma |